Study of cd38 and cd56 in chronic myeloid leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at two markers (CD38 and CD56) on cells from people with chronic myeloid leukemia (CML). It may help doctors understand the disease better and could guide treatment choices in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of CML.
- You must not have any other blood-related diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at a marker called CD47 (sometimes called a 'don't eat me' signal) in people with Chronic Myeloid Leukemia (CML). The goal is to understand how CD47 might affect the disease and find new ways to treat it.
This trial is a real-life study that collects information from people living with chronic myeloid leukemia (CML). It may help doctors understand how CML treatments are used in practice and how well they work over time.
This trial looks at a marker called CD56 in people who have been newly diagnosed with a blood cancer (a hematologic malignancy). The results may help doctors better understand the disease and guide future treatment choices.
This trial looks at two markers, CLL1 and CD45RA, found on some leukemia cells. It aims to help doctors better understand and treat acute myeloid leukemia (AML) by measuring these markers at diagnosis.
This research study examines blood cells from patients with chronic myelomonocytic leukemia (CMML), a rare blood cancer, to better understand how the disease develops and progresses. By studying your blood cells, researchers hope to learn more about what causes CMML and how to treat it better.
This study looks at two proteins on cancer cells (CD305 and CD85d) to better understand types of B-cell blood cancers. Results may help doctors tailor future treatments.
Hear when a new Chronic Myeloid Leukemia (CML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.